Rheumatoid Arthritis Clinical Trial
— HEOROfficial title:
Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis
Verified date | August 2011 |
Source | Abbott |
Contact | n/a |
Is FDA regulated | No |
Health authority | Greece: National Organization of Medicines |
Study type | Observational |
Evaluation of Health Related Quality of Life (HRQL) is of a paramount importance in
assessing the impact of rheumatoid arthritis on patients' health status, however when costs
associated with rheumatoid arthritis are also taken into account, the information provided
may lead to a more balanced view in analyzing the treatment of the disease.
In accordance with the above, the main objective this study was to evaluate the impact of
adalimumab treatment not only on patients' Health Related Quality of Life but also on the
cost of the disease management. In order to accomplish this the study has been focused on:
1. Estimating the direct and indirect cost incurred by adalimumab treatment.
2. Measuring the Health Related Quality of Life of rheumatoid arthritis patients under
adalimumab treatment.
3. Exploring the cost-utility relationship of rheumatoid arthritis patients treated with
adalimumab by combining the Health Related Quality of Life of rheumatoid arthritis
patients and direct as well as indirect costs due to RA.
More specifically, data related to patients' Health Related Quality of Life and cost
associated with rheumatoid arthritis will be recorded for one-year period, and collected at
four subsequent visits: baseline, month 3, 6 and 12. The visit before starting treatment
with adalimumab will be considered as baseline. This information was used to compare Health
Related Quality of Life and cost data before and after adalimumab initiation and therefore
identify the effect of adalimumab treatment in patients with rheumatoid arthritis.
Status | Completed |
Enrollment | 124 |
Est. completion date | June 2010 |
Est. primary completion date | June 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with moderate or severe active rheumatoid arthritis, who have been prescribed and are receiving adalimumab under normal clinical practice for at least one month and according to the approved Summary of Product Characteristics (SmPC) in the European Union. - Patients must be willing to consent to data being collected and provided to Abbott Laboratories. Exclusion Criteria: - Contraindications according to the SmPC - Patients should not participate in other observational Abbott study |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Greece | Site Reference ID/Investigator# 32052 | Athens | |
Greece | Site Reference ID/Investigator# 32068 | Athens | |
Greece | Site Reference ID/Investigator# 32069 | Athens | |
Greece | Site Reference ID/Investigator# 32071 | Crete | |
Greece | Site Reference ID/Investigator# 32072 | Ioannina | |
Greece | Site Reference ID/Investigator# 32073 | Larissa | |
Greece | Site Reference ID/Investigator# 32064 | Thessaloniki | |
Greece | Site Reference ID/Investigator# 32065 | Thessaloniki | |
Greece | Site Reference ID/Investigator# 32066 | Thessaloniki | |
Greece | Site Reference ID/Investigator# 32067 | Thessaloniki |
Lead Sponsor | Collaborator |
---|---|
Abbott | Institute of Political Economical & Social Researches, Greece |
Greece,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Estimation of the Direct and Indirect Cost Incurred by Adalimumab Treatment | Direct and indirect per-participant costs were estimated at Baseline (enrollment visit) for the 3-month period prior to initiation of adalimumab treatment, and at 3, 6 and 12 months following initiation of treatment. Direct costs included pharmaceutical costs, diagnostic and monitoring test costs, hospitalization costs, rheumatologist's costs, social insurance rheumatologist's costs, other specialists costs, physiotherapy costs, rehabilitation cost, home care cost, equipment cost and transportation cost. Indirect costs refer to loss of income due to rheumatoid arthritis disability. | Enrollment visit (Baseline), month 3, month 6, month 12 | No |
Primary | Health Related Quality of Life (European Quality of Life 5 Dimensions) | European Quality of Life 5 Dimensions (EQ-5D) is a generic health related quality of life instrument which assesses 5 health dimensions on a scale of 1 (no problems) to 5 (worst health). An overall score is derived ranging from -.59 to +1; a higher score indicates better health. | Enrollment visit (Baseline), month 3, month 6, month 12 | No |
Primary | Health Related Quality of Life (Health Assessment Questionnaire) | Health Assessment Questionnaire (HAQ) is designed to assess patients' abilities to perform activities of daily living. Scores range between 0 and 3, where higher values represent worse outcomes. | Enrollment visit (Baseline), month 3, month 6, month 12 | No |
Primary | Health Related Quality of Life (Medical Outcome Study Short Form 36) | Medical Outcome Study Short Form 36 (MOS SF-36) is a generic health related quality of life assessment that consists of 36 questions within 8 domains. Results from each domain are summarized and transformed into a scale ranging from 0 (worst) to 100 (best). | Enrollment visit (Baseline), month 3, month 6, month 12 | No |
Primary | Cost-Utility Relationship of Rheumatoid Arthritis Patients Treated With Adalimumab Using Incremental Cost-Effectiveness Approach (ICER) | The ICER calculation is based on comparison of differences in costs and utilities (based on Quality of Life Adjusted years [QALYs]) between Baseline and the 12 month visit. The ICER represents the extra costs that have to be incurred for one extra unit of perfect health to be produced. A treatment is determined to be cost-effective if the ICER is below a certain threshold (National Health Systems of European Union have suggested a threshold of 50,000 euros). | 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |